IGC Pharma

IGC Pharma We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing

in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

06/23/2026

Engineering takes many forms, from AI systems and research infrastructure to product development and operations.

On International Women in Engineering Day, we recognize the women across our teams whose technical expertise and problem-solving drive innovation forward.

Their work strengthens the foundation behind scientific progress.

Psilocybin is re-emerging in psychiatric research as scientists explore its potential role in mental health.Clinical stu...
06/21/2026

Psilocybin is re-emerging in psychiatric research as scientists explore its potential role in mental health.

Clinical studies are examining how different dosing approaches and structured psychological support may influence outcomes in conditions such as depression, anxiety, and addiction.

As research evolves, careful clinical evaluation remains essential to understanding both potential benefits and long-term safety.

Read the full article: https://igcpharma.com/psilocybin-and-mental-health/

Author: Dr. Juan Manuel Orjuela, Neuropsychiatrist

June is Alzheimer’s & Brain Awareness Month, a time to recognize the scale and complexity of a disease that affects mill...
06/15/2026

June is Alzheimer’s & Brain Awareness Month, a time to recognize the scale and complexity of a disease that affects millions of families worldwide.

Alzheimer’s remains one of the most challenging neurodegenerative conditions in modern medicine. Progress depends on rigorous clinical research, transparent data, and disciplined scientific development.

That commitment continues to guide our work every day.

06/12/2026

The Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer’s disease, sponsored by IGC Pharma, has reached its previously disclosed 146-patient randomization target.

Following completion of limited over-enrollment and patient follow-up, IGC Pharma expects to proceed with database lock, site closeout, and subsequent topline analysis.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-reaches-previously-disclosed-123000740.html

06/10/2026

Ascendiant Capital Markets has issued an updated equity research report on IGC Pharma, raising its price target to $5.50 per share.

All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy or conclusions contained in any analyst report.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/ascendiant-capital-markets-raises-igc-123000485.html

06/03/2026

The Icahn School of Medicine at Mount Sinai in New York has been added as a clinical site in IGC Pharma’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.

The trial at the site is led by Dr. Rachel Fremont, MD, PhD, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. Her work focuses on the clinical and biological characterization of psychiatric symptoms in neurodegenerative disorders, including Alzheimer’s disease and related dementias.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-adds-mount-sinai-123000813.html?guccounter=1

Caring for someone living with Alzheimer’s often means navigating uncertainty from day to day.Establishing a consistent ...
05/31/2026

Caring for someone living with Alzheimer’s often means navigating uncertainty from day to day.

Establishing a consistent daily care plan can help create structure, reduce stress, and provide a greater sense of stability for both individuals and caregivers. Small adjustments, from timing activities thoughtfully to incorporating familiar routines, can make a meaningful difference.

Thoughtful planning supports more manageable, predictable days.

On Clinical Trials Day, we recognize the role that structured, patient-centered research plays in advancing medicine.Cli...
05/20/2026

On Clinical Trials Day, we recognize the role that structured, patient-centered research plays in advancing medicine.

Clinical trials rely on scientific rigor, regulatory responsibility, and the trust of the patients and investigators who make progress possible. Each study helps deepen our understanding of complex conditions such as Alzheimer’s disease and contributes to the development of more informed care approaches.

At IGC Pharma, our clinical development work is guided by integrity, transparency, and a commitment to responsible progress. Meaningful advancement requires not only innovation, but careful and disciplined ex*****on.

05/18/2026

New Tau-PET biomarker research by IGC Pharma was presented at the 2026 Global Tau Conference.

The poster, titled “Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer’s Disease Progression in Amyloid-Positive APOE4 Carriers,” evaluated whether Shannon entropy can quantify spatial heterogeneity in tau pathology and may help predict future tau accumulation using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).

This work aligns with IGC Pharma’s broader strategy of integrating advanced analytics, neuroimaging, and AI-driven approaches to strengthen its Alzheimer’s research platform alongside the ongoing Phase 2 CALMA clinical trial.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-present-tau-pet-120000503.html

Alzheimer’s disease affects more than memory. It can influence how a person thinks, communicates, and responds to their ...
05/13/2026

Alzheimer’s disease affects more than memory. It can influence how a person thinks, communicates, and responds to their surroundings over time.

For families and caregivers, these changes can be difficult to interpret. Understanding how Alzheimer’s impacts memory, cognition, and behavior provides important context for navigating daily life and care decisions.

Informed awareness supports more structured conversations and more thoughtful care planning.

Address

Potomac, MD

Telephone

+13019830998

Website

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to IGC Pharma:

Shortcuts

Featured

Share

Category